MOTS-c is a 16-amino-acid mitochondrial-derived peptide that acts in preclinical models as a metabolic regulator, promoting activation of the AMPK energy-sensing pathway and influencing insulin sensitivity and glucose handling. First described by Cedars-Sinai researchers around 2015, it is often called an exercise mimetic, but the honest bottom line comes first: it is an investigational compound, not approved by the FDA for any use, and most of its supporting evidence sits at the cell-culture and rodent level rather than in human trials. Material sold online is typically labeled for research use only.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region that regulates metabolism through AMPK in preclinical models, and it remains investigational and not FDA-approved for any medical use.
The name MOTS-c spells out its own origin: mitochondrial open reading frame of the twelve S ribosomal RNA type-c, a coding sequence that sits inside the 12S rRNA region of the mitochondrial genome rather than in nuclear DNA. That detail is what makes the peptide notable, because nearly all of the body's signaling peptides are transcribed from the nucleus, while MOTS-c is one of a small set encoded by the mitochondria's own circular genome.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide first characterized by Cedars-Sinai researchers in 2015 and encoded within the 12S rRNA region of the mitochondrial genome, placing it in the same family as humanin and the SHLPs.
The mechanism most consistently reported for MOTS-c centers on AMP-activated protein kinase (AMPK), the cell's master sensor of energy status. In preclinical work the peptide promotes AMPK activation, which raises glucose uptake and improves how sensitively tissues respond to insulin, and under metabolic stress it does something unusual for a small peptide: it translocates into the nucleus to help regulate stress-response and antioxidant genes. This mechanistic picture is drawn largely from cell and animal experiments, and the precise receptors and human-relevant pathways for an administered dose are still being worked out.
In preclinical models MOTS-c activates the AMPK energy-sensing pathway to raise glucose uptake and insulin sensitivity, and under metabolic stress it translocates to the nucleus to regulate NRF2-linked antioxidant genes, which is why the literature describes it as an exercise mimetic.
The benefits studied for MOTS-c cluster around metabolism, and separating what is proposed from what is proven matters more here than anywhere else on the topic. In rodent models the peptide has improved insulin sensitivity, lowered blood glucose, and reduced diet-induced weight gain, which is why it is framed as a candidate for insulin resistance, type 2 diabetes, and obesity research. Every one of these findings currently rests on animal or cell studies or on small early human observations, not on the large controlled human trials that would establish a clinical benefit in people.
MOTS-c has improved insulin sensitivity, lowered blood glucose, and reduced diet-induced weight gain in rodent models, but every proposed metabolic, performance, and anti-aging benefit rests on animal or small early human data rather than large controlled human trials.
MOTS-c sits where two active areas of aging research meet: mitochondrial biology and metabolic health. Declining mitochondrial function is a recognized hallmark of aging, and because MOTS-c is a mitochondrial signal that supports metabolic resilience, it has been proposed as one molecular link between failing mitochondria and age-related decline. The distinction that marketing tends to blur is healthspan versus lifespan, and the evidence separates sharply between the two.
| Aging claim | What the record shows | Evidence strength |
|---|---|---|
| Circulating levels fall with age | Human observational measurements report the association | Correlational only |
| Better function in later life | Older mice show improved performance and metabolic markers | Animal models |
| Lifespan extension in humans | No direct evidence exists | Absent |
Circulating MOTS-c levels decline with age and administering it has improved function in older mice, but no direct evidence shows it extends lifespan in humans, so its longevity role remains a healthspan hypothesis rather than a proven anti-aging effect.
The human evidence for MOTS-c is thin and largely indirect. Most of what is known comes from cell-culture and rodent experiments, and where people appear in the literature it is usually through observational studies that measure the body's own circulating MOTS-c and correlate it with age, exercise capacity, or metabolic disease. Measuring a molecule the body already makes is fundamentally different from administering it as a drug, so those studies cannot show that extra MOTS-c produces a health benefit.
As of now there are essentially no published placebo-controlled human trials of administered MOTS-c, leaving no established human dose, no long-term safety data, and no confirmation that its animal-model benefits translate to people.
The most important safety fact about MOTS-c is how little is genuinely known. With no large controlled human trials, there is no established side-effect profile, no characterized safe dose range, and no long-term human safety data, and that absence of evidence is itself the primary concern. A compound that has not been tested rigorously in people cannot be assumed safe just because early animal work raised no flags.
MOTS-c has no established side-effect profile, safe dose range, or long-term human safety data, and because research-chemical supply is not made under pharmaceutical controls, independently tested peptides have been found underdosed, degraded, mislabeled, or contaminated with bacterial endotoxins.
MOTS-c is not an approved drug. The FDA has not approved it for any therapeutic indication, and it is sold predominantly as a research chemical carrying a research use only or not for human consumption label, a designation that frames the material for laboratory investigation rather than treatment. That label does not make the compound tested or safe; it is largely a way to sell a substance that has never been through drug approval.
| Dimension | MOTS-c (research chemical) | Approved prescription peptide |
|---|---|---|
| FDA status | Not approved for any use | Approved indication and label |
| How it is sold | "Research use only" label | Dispensed under medical supervision |
| Human safety/efficacy data | Not established | Demonstrated to regulators |
| Sport / anti-doping | Scrutinized metabolic modulator | Governed by its approved use |
MOTS-c holds no FDA approval and is sold as a research-use-only chemical rather than a prescription medication, a status that differs fundamentally from an approved peptide with demonstrated safety, an approved label, and medical supervision, and its metabolic action places it among substances anti-doping authorities scrutinize.
There is no established, approved, or medically endorsed human dose for MOTS-c, and dosing is where the gap between marketing and evidence is widest. In laboratory research the peptide has most often been given by injection, but the animal doses used were selected for specific rodent experiments rather than calibrated as safe or effective human doses, and scaling those numbers to people is not scientifically valid without dedicated human pharmacology studies.
MOTS-c has no established human dose; in research it has been given by injection as a reconstituted lyophilized powder, but the animal doses used do not scale to people, and any validated dose would require controlled pharmacokinetic, dose-ranging, and safety studies that the research-chemical supply chain does not provide.
Educational use only. This article describes what the published scientific and clinical literature reports about MOTS-c. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
